Sight Sciences, Inc. (SGHT)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$8.99-1.10%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sight Sciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	23.71M
EPS	—	-0.128
Annual ending 2026-12-31
Revenue	—	90.32M
EPS	—	-0.539
Annual ending 2027-12-31
Revenue	—	100.96M
EPS	—	-0.466

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage patent litigation outcomes without major losses	A supporting condition in Sight Sciences, Inc.'s published investment case. The stated target is No adverse ruling causing major financial harm.	Recovered	Unfavorable court ruling causing large damages or injunction	Qualitative: Favorable final judgment vs no adverse ruling April 2026 final judgment in SGHT's favor; no new adverse litigation events reported. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating expenses stay below $96 million in 2026	The company focuses on managing operating expenses near $93-$96 million.	Intact	Operating expenses exceed $96 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches at least $83 million in 2026	A primary condition in Sight Sciences, Inc.'s published investment case. The stated target is >=83 million USD.	Intact	Revenue falls below $83 million in FY26	Revenue: $23.388M FY2026-Q2; GAAP. Published target: >=83 million USD. Target period is not explicitly aligned with this observation. Source published Aug 5, 202623,388,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9ff2920b-9b52-44b0-a8d3-fdb1225314da. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew 20% year-over-year in 2026-Q2 to $23.4 million, and management raised full-year 2026 revenue guidance from $83-$89 million in 2026-Q1 to $88-$92 million in 2026-Q2. The trajectory is delivering with accelerating revenue growth and upward guidance revisions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.47

Unavailable → $-0.47 · observed estimates

FY2027 revenue$0.10B

$0.10B → $0.10B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$95,658,300	1 / 6
2026-07-25	Unavailable	$95,658,300	1 / 6
2026-07-26	Unavailable	$95,658,300	1 / 6
2026-07-27	Unavailable	$95,658,300	1 / 6
2026-07-28	Unavailable	$95,658,300	1 / 6
2026-07-29	$-0.45	$95,755,680	5 / 7
2026-07-30	Unavailable	$95,658,303	3 / 5
2026-07-31	$-0.45	$95,755,682	5 / 5
2026-08-01	$-0.45	$95,755,682	5 / 5
2026-08-02	$-0.45	$95,755,680	5 / 7
2026-08-03	$-0.67	$95,755,682	5 / 5
2026-08-04	$-0.45	$95,755,680	5 / 7
2026-08-05	$-0.67	$95,755,682	5 / 5
2026-08-06	$-0.45	$95,755,680	5 / 7
2026-08-08	$-0.43	$101,066,120	5 / 7
2026-08-09	$-0.55	$99,837,553	5 / 5
2026-08-10	$-0.43	$101,066,120	5 / 7
2026-08-12	$-0.55	$99,837,553	5 / 5
2026-08-13	$-0.43	$101,066,120	5 / 7
2026-08-14	$-0.55	$99,837,553	5 / 5
2026-08-15	$-0.55	$99,837,553	5 / 5
2026-08-16	$-0.55	$99,837,553	5 / 5
2026-08-17	$-0.55	$99,837,553	5 / 5
2026-08-18	$-0.55	$99,837,553	5 / 5
2026-08-19	$-0.55	$99,837,553	5 / 5
2026-08-20	Unavailable	$101,066,124	4 / 5
2026-08-21	Unavailable	$101,066,124	4 / 5
2026-08-22	Unavailable	$101,066,124	4 / 5
2026-08-23	Unavailable	$101,066,124	4 / 5
2026-08-24	Unavailable	$101,066,124	4 / 5
2026-08-25	Unavailable	$101,066,124	4 / 5
2026-08-26	Unavailable	$101,066,124	4 / 5
2026-08-27	Unavailable	$101,066,124	4 / 5
2026-08-28	Unavailable	$101,066,124	4 / 5
2026-08-29	Unavailable	$101,066,124	4 / 5
2026-08-30	Unavailable	$101,066,124	4 / 5
2026-08-31	Unavailable	$101,066,124	4 / 5
2026-09-01	Unavailable	$101,066,124	4 / 5
2026-09-02	Unavailable	$101,066,124	4 / 5
2026-09-03	Unavailable	$101,066,124	4 / 5
2026-09-04	Unavailable	$101,066,124	4 / 5
2026-09-05	Unavailable	$101,066,124	4 / 5
2026-09-06	Unavailable	$101,066,124	4 / 5
2026-09-07	Unavailable	$101,066,124	4 / 5
2026-09-08	Unavailable	$101,066,124	4 / 5
2026-09-09	Unavailable	$101,066,124	4 / 5
2026-09-10	Unavailable	$101,066,124	4 / 5
2026-09-11	Unavailable	$101,066,124	4 / 5
2026-09-12	Unavailable	$101,066,124	4 / 5
2026-09-13	Unavailable	$101,066,124	4 / 5
2026-09-14	Unavailable	$101,066,124	4 / 5
2026-09-15	Unavailable	$101,066,124	4 / 5
2026-09-16	Unavailable	$101,066,124	4 / 5
2026-09-17	Unavailable	$101,066,124	4 / 5
2026-09-18	Unavailable	$101,066,124	4 / 5
2026-09-19	Unavailable	$101,066,124	4 / 5
2026-09-20	Unavailable	$101,066,124	4 / 5
2026-09-21	Unavailable	$101,066,124	4 / 5
2026-09-22	Unavailable	$101,066,124	4 / 5
2026-09-23	Unavailable	$101,066,124	4 / 5
2026-09-24	Unavailable	$101,066,124	4 / 5
2026-09-25	Unavailable	$101,066,124	4 / 5
2026-09-26	Unavailable	$101,066,124	4 / 5
2026-09-27	Unavailable	$101,066,124	4 / 5
2026-09-28	Unavailable	$101,066,124	4 / 5
2026-09-29	Unavailable	$101,066,124	4 / 5
2026-09-30	Unavailable	$101,066,124	4 / 5
2026-10-01	Unavailable	$101,066,124	4 / 5
2026-10-02	Unavailable	$101,066,124	4 / 5
2026-10-03	Unavailable	$101,066,124	4 / 5
2026-10-04	Unavailable	$101,066,124	4 / 5
2026-10-05	Unavailable	$101,066,124	4 / 5
2026-10-06	Unavailable	$101,066,124	4 / 5
2026-10-07	Unavailable	$101,066,124	4 / 5
2026-10-08	Unavailable	$101,066,124	4 / 5
2026-10-09	Unavailable	$101,066,124	4 / 5
2026-10-10	Unavailable	$101,066,124	4 / 5
2026-10-11	Unavailable	$101,066,124	4 / 5
2026-10-12	Unavailable	$101,066,124	4 / 5
2026-10-13	Unavailable	$101,066,124	4 / 5
2026-10-14	Unavailable	$101,066,124	4 / 5
2026-10-15	Unavailable	$101,066,124	4 / 5
2026-10-16	Unavailable	$100,957,859	4 / 5
2026-10-17	Unavailable	$100,957,859	4 / 5
2026-10-18	$-0.52	$100,957,859	5 / 6
2026-10-19	$-0.47	$100,957,859	5 / 6
2026-10-20	$-0.47	$100,957,859	5 / 6
2026-10-21	$-0.47	$100,957,859	5 / 6
2026-10-22	$-0.47	$100,957,859	5 / 6
2026-10-23	$-0.47	$100,957,859	5 / 6
2026-10-24	$-0.47	$100,957,859	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	2
2026-06-01	4	2
2026-07-01	5	2
2026-08-01	5	2
2026-09-01	5	2
2026-10-01	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 15

$14.00New observation · no comparable prior

$0$7.70$15.40

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Operating expenses stay below $96 million in 2026Direct metric needs a verified mapping
Revenue reaches at least $83 million in 2026Revenue: $23.388M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-61.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sight Sciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

SGHT is a high-risk growth business, not yet a proven durable compounder, because it remains loss-making. Its long-term thesis is on watch: revenue and market access are improving, while recent performance has lagged its industry group.

What's priced into Sight Sciences, Inc.

The valuation model describes a durable premium to peers, with no gap between its expectations measure and what is priced in; confidence in that model is low. The evidence does not point to a clear expectations cushion, so the premium depends on continued growth and better execution.

What the fundamentals likely do

Near-term results show revenue up 20% year over year in 2026-Q2, lower adjusted operating expenses, and higher full-year revenue guidance. Dry-eye revenue also expanded sharply, but the company remains loss-making and expense progress is mixed; a recent earnings miss and weaker performance than its industry group add risk.

What Sight Sciences, Inc. hinges on

A favorable scenario depends on another guidance increase after the prior cut noted in the forward evidence, along with continued growth in dry-eye access and revenue. A weaker jobs trend could raise recession concerns for cyclical healthcare names, while earnings and guidance from sector peers may shape the backdrop.